|
職名 |
産学官連携講座教授 | |
|
氏名 |
渡辺 隆 | |
|
生年月 |
| |
所属 |
部局 |
医学系研究科 |
|
学科・専攻 |
| |
|
講座 |
| |
|
教育研究分野 |
| |
|
TEL |
059-231-5380 | |
|
FAX |
059-231-5397 | |
|
E-mail |
twatanabe@doc.medic.mie-u.ac.jp | |
|
個人のホームページ |
| |
|
学歴 |
1986年3月 千葉大学医学部卒業
| |
|
学位 |
1995年3月 名古屋大学医学部第一内科にて医学博士取得 | |
|
所属学会 |
日本内科学会・日本癌学会・日本血液学会・日本癌免疫学会・日本遺伝子治療学会・日本臨床腫瘍学会・日本骨髄腫学会・日本リンパ網内系学会・日本輸血細胞治療学会 | |
|
社会活動 |
| |
|
職歴 |
1986年5月 名古屋第二赤十字病院勤務（研修医）
1988年5月 同 上 血液内科動務 1990年4月 東京都立駒込病院化学療法科勤務 国立小児病院小児医療研究センターウイルス研究室にて共同研究 1992年7月 名古屋大学医学部第一内科学教室帰局 1995年10月 Department of Medicine, UCSD, Flossie Wong-Staal教授のもとに留学 1997年2月 Departments of Experimental Surgery and Genetics, Duke University Medical Center, Bruce A. Sullenger博士のもとに留学 2000年4月 国立がんセンター中央病院 臨床検査部血液検査室勤務 2002年4月 国立がんセンター中央病院 特殊病棟部11B 病棟医長 兼 臨床検査部血液検査室医長 2006年1月 国立がんセンター中央病院特殊病棟部11B病棟医長 2010年6月 独立行政法人 国立がん研究センター中央病院 血液腫瘍科・造血幹細胞移植科病棟医長 2012年7月 独立行政法人 国立がん研究センター中央病院 血液腫瘍科 病棟医長 2013年7月 小牧市民病院血液内科部長 2014年4月 同病院血液内科部長・輸血科部長 2014年9月 同病院血液内科部長・輸血科部長・外来化学療法センター長 2016年4月 現職 | |
|
学術（芸術）賞 |
| |
|
専門分野 |
血液腫瘍・多発性骨髄腫・悪性リンパ腫 | |
|
現在の研究課題 |
癌免疫・T細胞療法 | |
|
担当科目 |
| |
|
主な業績等 |
1. Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol 172:745-756, 2016.
2. Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M. Lipopolysaccharide-induced CXCL mRNA level and six stimulant-mRNA combinations in whole blood: novel biomarkers for bortezomib responses obtained from a prospective multicenter trial for patients with multiple myeloma. PLoS One 10:e0128662. doi:10.1371/journal.pone.0128662. 3. Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M. Phytohemagglutinin-induced IL2 mRNA in whole blood can predict bortezomib-induced peripheral neuropathy for multiple myeloma patients. Blood Cancer J Oct 4;3:e150. doi: 10.1038/bcj.2013.47. 4. Fukuhara S, Watanabe T, Munakata W, Mori M, Maruyama D, Kim SW, Kobayashi Y, Taniguchi H, Maeshima AM, Tanosaki R, Matsuno Y, Tobinai K. Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution. Eur J Haematol 87: 434-440, 2011. 5. Watanabe T, Tobinai K, Shibata T, Tsukasaki K, Morishima Y, Maseki N, Kinoshita T, Suzuki T, Yamaguchi M, Ando K, Ogura M, Taniwaki M, Uike N, Takeuchi K, Nawano S, Terauchi T, Hotta T. Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell Non-Hodgkin's Lymphoma: JCOG 0203 Trial. J Clin Oncol 29: 3990-3998, 2011. 6. Watanabe T. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 19: 1113-1127, 2010. 7. Maruyama D, Watanabe T, Maeshima AM, Nomoto J, Taniguchi H, Azuma T, Mori M, Munakata W, Kim SW, Kobayashi Y, Matsuno Y, Tobinai K. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 92: 732-743, 2010. 8. Watanabe T, Nagase K, Chosa M, Tobinai K. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer 103: 1580-1587, 2010. 9. Watanabe T, Kinoshita T, Itoh K, Yoshimura K, Ogura M, Kagami Y, Yamaguchi M, Kurosawa M, Tsukasaki K, Kasai M, Tobinai K, Kaba H, Mukai K, Nakamura S, Ohshima K, Hotta T, Shimoyama M. Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. Leuk Lymphoma 51: 813-821, 2010. 10. Watanabe T, Kato H, Kobayashi Y, Yamasaki S, Morita-Hoshi Y, Yokoyama H, Morishima Y, Ricker JL, Otsuki T, Maesima AM, Matsuno Y, Tobinai K. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101: 196-200, 2010. 11. Tobinai K, Watanabe T, Tanimoto K, Maruyama D, Nakata M, Itoh K, Morishima Y, Ogura M, Usui N, Kasai M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y. Phase I/II and pharmacokinetic study of cladribine with 2-hour infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci 100: 1344-1350, 2009. 12. Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K, Itoh K, Okamoto S, Taniwaki M, Tsukamoto N, Okumura H, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Endo K. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 100: 158-164, 2009. 13. Maruyama D, Watanabe T, Heike Y, Nagase K, Takahashi N, Yamasaki S, Waki F, Yokoyama H, Kim SW, Kobayashi Y, Aizawa S, Tobinai K. Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. Int J Hematol 88: 396-402, 2008. 14. Ono M, Watanabe T, Shimizu C, Hiramoto N, Goto Y, Yonemori K, Kouno T, Ando M, Tamura K, Katsumata N, Fujiwara Y. Therapy-related acute promyelocytic leukemia caused by hormonal therapy and radiation in a patient with recurrent breast cancer. Jpn J Clin Oncol 38: 567-570, 2008. 15. Yokoyama H, Watanabe T, Maruyama D, Kim SW, Kobayashi Y, Tobinai K. Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature. Int J Hematol 88: 443-447, 2008. 16. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K. Primary Bone Lymphoma: a New and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol 37: 216-223, 2007. 17. Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Teraucui T, Nawano S, Matsusako M, Matsuno Y, NakamuraS, Mori S, Ohashi Y, Hayashi M, Serui T, Hotta T. Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin’s lymphoma. J Clin Oncol 24: 174-180, 2006. 18. Sekiguchi N, Watanabe T, Kobayashi Y, Inokuchi C, Kim SW, Yokota Y, Tanimoto K, Matsuno Y, Tobinai K. The application of molecular analysis for primary granulocytic sarcoma with specific chromosomal translocation. Int J Hematol 82: 210-214, 2005. 19. Watanabe T, Terui S, Itoh K, Terauchi T, Igarashi T, Usubuchi N, Nakata M, Nawano S, Sekiguchi N, Kusumoto S, Tanimoto K, Kobayashi Y, Endo K, Seriu T, Hayashi M, Tobinai K. Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate (90Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. Cancer Sci 96: 903-910, 2005. 20. Watanabe T, Sullenger BA. RNA repair: a novel approach to gene therapy. Advanced Drug Delivery Reviews 44: 109-118, 2000. 21. Watanabe T, Sullenger BA. Trans-splicing ribozyme-mediated repair of tumor suppressor p53 mutant mRNAs in human cancer cells. Proc Natl Acad Sci USA 97: 8490-8494, 2000. 22. Tomita A, Watanabe T, Kosugi H, Ohashi H, Uchida T, Kinoshita T, Mizutani S, Hotta T, Seto M, and Saito H. Truncated c-Myb expression in the human leukemia cell line TK-6. Leukemia 12: 1422-1429, 1998. 23. Ichikawa A, Kinoshita T, Watanabe T, Kato K, Nagai H, Tsushita K, Saito H, Hotta T. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. New Engl J Med 337: 529-534, 1997. 24. Watanabe T, Ichikawa A, Saito H, Hotta T. Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma 21: 391-397, 1996. 25. Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T. Mutational analysis of the CDKN2 (MTS1/P16 ink4A) gene in primary B-cell lymphomas. Blood 86: 2724-2731, 1995. 26. Watanabe T, Kataoka T, Mizuta S, Kobayashi M, Uchida T, Imai K, Wada H, Kinoshita T, Murate T, Mizutani S, Saito H, Hotta T. Establishment and characterization of a novel cell line, TK-6, derived from T cell blast crisis of chronic myelogenous leukemia, with the secretion of parathyroid hormone-related protein. Leukemia 9: 1926-1934, 1995. 27. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 84: 3158-3165, 1994. | |